MTX therapy is discontinued because of adverse effects. 1,2 Genetic predisposition may play a role in therapy individualization. There are numerous potential enzymes and transport proteins participating in MTX transport to the cell and in its metabolism and cell excretion. The main enzymes binding to TCII negatively affects the process of cobalamin transport to cells and becomes one of the causes of vitamin B 12 deficiency. Several polymorphisms have been described within the gene encoding TC. These changes may affect vitamin B 12 binding to TC or alter the recognition of holo-TC by TC receptors on target cells (FIGURe 1). 14 A number of studies on the polymorphisms of genes involved in the MTX metabolism have focused on the simultaneous evaluation of multiple polymorphisms in an attempt to determine a genetic profile that would be characterized by the highest efficacy and lowest incidence of adverse effects. [15] [16] [17] The aim of this study was to determine the effect of polymorphisms in the MTHFR, RFC-1, TYMS, GGH, and TC genes on the efficacy of MTX therapy and related adverse effects in patients with RA.
PATIeNTs AND meThODs A total of 273 patients with RA were included in the study. All patients were treated with MTX for at least 6 months or the drug was discontinued earlier because of adverse effects. The characteristics of the patients are presented in TABle 1. Thirty-three patients were excluded from the analysis because they missed some of the follow-up visits and the data regarding the activity of the disease and adverse effects were incomplete. The final analysis included 240 patients: 196 women (82%) and 44 men (18%). During the follow-up period, 82 patients (34%) discontinued the therapy with MTX: 40 (17%) because of side effects and 42 (17.5%) because of no improvement.
The following inclusion criteria were applied: 1) consent to participate in the study; 2) confirmed RA based on the criteria of the American Rheumatology Association; 3) active form of the disease: erythrocyte sedimentation rate (ESR), >30 mm/h, or C-reactive protein (CRP), >1.5 mg/dl, or both; minimum 4 painful and 3 swollen joints; Disease Activity Score 28 (DAS28), >3.2; 4) age over 18 years; 5) women and men with reproductive potential had to use reliable contraception; 6) use of nonsteroidal anti-inflammatory drugs and corticosteroids in stable doses allowed.
The exclusion criteria were as follows: 1) pregnancy or breastfeeding; 2) coexistence of other systemic diseases of connective tissue besides RA; 3) clinically significant impairment of hepatic and renal function; 4) alcohol abuse; 5) infection with hepatotropic viruses; 6) infections resistant to therapy; 7) ongoing history of cancer if no cure was achieved; 8) uncontrolled diabetes; and 9) patient unwilling or unable to cooperate.
The study was approved by the Ethics Committee at the Wroclaw Medical University.
MTX was administered orally at an initial dose of 10 to 15 mg once a week. If at least a moderate improvement was not achieved and there were no significant adverse effects, the dose was titrated to a maximum level of 25 mg/wk.
Clinical and biochemical activity of the disease was evaluated in the study. Clinical evaluation and the MTX metabolic pathway are presented in FIGURe 1. MTX is actively transported to the cell by a protein called reduced folate carrier (RFC-1). RFC-1 polymorphisms may lead to alteration of the enzyme's activity. 3 Inside the cell, MTX undergoes polyglutamination with folylpolyglutamyl synthetase (FPGS). Polyglutamyl MTX forms (MTXPG) are less rapidly expelled from the cell; therefore, MTX's half-time inside the cell is extended. Reversion of polyglutamination reaction, requiring the participation of the folylpolygammaglutamyl hydrolase enzyme (GGH), facilitates MTX removal from the cell. High GGH concentrations were associated with resistance to MTX. 4 In recent years, several single--nucleotide polymorphisms within the GGH gene that may affect GGH activity have been identified. The polymorphism c.-401C>T (rs3758149) in the GGH promoter region increases GGH expression and may affect intercellular MTXPG concentrations. 5 Enzymes affected by MTX are, among others, thymidylate synthase (TYMS) and methylenetetrahydrofolate reductase (MTHFR). TYMS is one of the basic enzymes necessary for DNA synthesis. MTXPG, by inhibiting TYMS activity, contributes to a reduction of the folate pool and inhibition of cell proliferation. 6 Three polymorphisms in the TYMS gene have been studied so far: a varied number of repetitions of a 28-nucleotide zone, a G>C exchange in the 12th nucleotide in the second repetition of the 3R allele, and a 6-bp deletion in the 3´UTR (3´UTR 6-bp ins/del, rs16430). TYMS enzymatic activity rises with an increasing number of repeated 28-bp sequences. 7 Another mechanism of MTX's action is the indirect inhibition of folate metabolism by methylenetetrahydrofolate reductase blocking. MTX affects the general pool of intercellular folates and thus affects the enzyme. Martin et al. 8 analyzed the DNA of 240 individuals of various races and demonstrated the presence of 62 single-nucleotide polymorphisms. The best-known polymorphism, c.677C>T (rs1801133) of the MTHFR gene, leads to a replacement of alanine by valine in codon 222 (pAla222Val). This results in the formation of a thermo-labile MTHFR variant with reduced activity of the enzyme. The c.677C>T polymorphism may lead to a reduction of 5-methyltetrahydrofolate concentrations and accumulation of 5,10-methylenetetrahydrofolate resulting in hyperhomocysteinemia.
9,10 The second polymorphism, c.1298A>C (rs1801131) of MTHFR, leads to the substitution of alanine for glutamine at codon 429 (p.Glu420Ala). 11 The change causes a reduction in the enzyme's activity by approximately 40%. Data on the effect of polymorphisms in the MTHFR gene on the efficacy of MTX therapy and the development of adverse effects during RA therapy are ambiguous.
12,13
Hyperhomocysteinemia may be the result of folic acid and vitamin B 12 deficiency, among others. Approximately 25% of vitamin B 12 is bound to transcobalamin II (TCII). Improper cobalamin the therapy and at 2, 4, and 6 months of the follow-up.
Considering adverse effects, the patients were divided into 3 groups: patients with no adverse effects; with mild and moderate adverse effects (1st and 2nd degree); and with severe adverse effects and effects resulting in the discontinuation of the MTX therapy (3rd and 4th degree).
Adverse effects were divided into those associated with the gastrointestinal tract, respiratory and nervous system, increased activity of aminotransferases, hematological complications, hair loss, infections, and others. All patients received from 5 to 15 mg of folic acid 24 to 48 h after MTX administration.
A total of 7 polymorphisms were evaluated. Six of them were associated with MTX metabolism and mechanism of action (MTHFR c.677C>T was based on a medical history, number of painful and swollen joints, pain intensity assessed by the patient on a 100-mm visual analogue scale, disease activity assessed by the patient and physician as well as the results of laboratory tests (ESR, CRP). The parameters allowed us to determine the improvement according to the criteria of the European League Against Rheumatism (EULAR). Based on the efficacy of the therapy, patients were divided into 3 groups: group A, no response (DAS28 ≤0.6); group B, moderate efficacy of the therapy (0.6 <DAS28 ≤1.2); group C, good response to the therapy (DAS28 >1.2).
Moreover, in some analyses, a comparison was made between patients with no response (nonresponders) and those who had moderate or good response (responders), which was due to the limited number of the patients in each group (TABle 1) .
Safety of MTX was analyzed on the basis of a medical history, physical examination, and selected laboratory tests. The clinical and laboratory tests were completed before the start of was demonstrated at 2 and 6 months in 101 patients (42%) and 104 patients (43%), respectively, and no improvement or deterioration was demonstrated in 72 patients (30%) and 57 patients (24%), respectively. No effect of sex, the period of RA progression, use of corticosteroids, or smoking on the efficacy of the therapy was demonstrated. However, higher efficacy of the therapy was demonstrated in patients with a less active course of the disease at the beginning of the therapy (P <0.01) and if MTX was used as the first DMARD (P <0.01) (TABle 1) .
Adverse effects in patients treated with methotrexate Adverse effects occurred in 128 patients (53%), and in 40 of them (17%), they resulted in the discontinuation of the therapy (TABle 2) . We observed that adverse effects were significantly more common in patients with a more active course of the disease, in whom MTX was used as a second DMARD, and hair loss was more common among older patients. Serious adverse effects were significantly more common when MTX was introduced in patients with RA lasting for a longer period of time (P <0.01). Patients were divided into 2 subgroups with regard to disease activity: those with DAS28 >4 and with DAS28 <4. Adverse effects were observed significantly more often in patients with more active RA at the start of MTX therapy (OR, 6.96; P = 0.002).
Gene polymorphisms and efficacy of therapy and adverse effects The genotype distribution of the MTHFRc.677C>T (rs1801133) and c.1298A>C (rs1801131), RFC-1 c.80A>G, TYMS 2R/3R (rs45455694) and 6bp ins/del (rs16430), GGH c.-401C>T (rs3758149), and TC c.593T>C polymorphisms was determined in 240 patients.
Compliance with the Hardy-Weinberg equilibrium (HWE) was shown for MTHFRc.677C>T (P = 0.93), TYMS 2R/3R (P = 0.06), TYMS 6bp ins/del (P = 0.97), RFC-1 c.80A>G (P = 0.93) and the GGH c.-401C>T (P = 0.45). A lack of Genomic DNA was extracted from peripheral blood leukocytes with the Blood Mini Kit (A&A Biotechnology, Gdynia, Poland). The MTHFR c.677C>T, MTHFR c.1298A>C, TYMS 3`UTR1494insdel6bp, RFC-1, and GGH polymorphisms were analyzed by polymerase chain reaction (PCR)-restriction fragment length polymorphism. Amplification of DNA was performed in a PCR thermal cycler (MJ Research, Quebec, Canada). Digestion of the PCR products was conducted by appropriate restriction enzymes, namely, HinfI, MboII, DraiI, CfoI, and BslI (Fermentas, Vilnius, Lithuania), respectively. The polymorphisms in the TCII were analyzed by the PCR-amplification refractory mutation system. PCR products were analyzed by gel electrophoresis on agarose gel (2.5%) and visualized with SybrGREEN (Lonza, Rockland, Maine, United States).
To characterize and compare responders and nonresponders, descriptive statistics were calculated for age, duration of the disease, and evaluation of the inflammatory process activity using DAS28. The statistical significance of differences between the mean values or fraction of the parameters was determined with the t test for independent samples or the χ 2 test.
Relationships between: 1) polymorphisms (polymorphism combinations) and efficacy of the therapy; 2) polymorphisms (polymorphism combinations) and adverse effects; and 3) polymorphisms and duration of RA in years before the introduction of MTX, use of MTX as the first/ next disease-modifying antirheumatic drugs (DMARDs), RA activity, rapid reaction to MTX, RA grade, MTX discontinuation, use of corticosteroids, and smoking were tested with the χ 2 test. The odds ratio (OR) and P value were calculated for 4-field tables.
ResUlTs Therapy efficacy A good response to therapy according to the EULAR criteria was observed at 2 months in 67 patients (28%) and at 6 months in 79 (33%). A moderate improvement compliance with HWE was observed for MTHFRc. 1298A>C (P <0.001) and TC c.593T>C (P <0.001).
The study showed no effect of the polymorphisms on the initial activity of the disease and age at the onset of the disease. A more rapid positive response to MTX therapy was demonstrated in MTHFR 677CC homozygotes (OR, 3.4; P = 0.001), and a higher number of patients in whom the therapy was discontinued because of adverse effects was observed among patients with the T allele (OR, 2.5; P = 0.02). There was no other association between the 7 single-nucleotide polymorphisms and the efficacy of MTX treatment.
The incidence of adverse effects in the study group in relation to individual polymorphisms was also analyzed (TABle 3) . The effect of combinations of the RFC-1, TYMS, GGH, and MTH-FR genotypes on the incidence of adverse effects is presented in TABle 4. Adverse effects occurred significantly more often in patients with genotypes MTHFR 677TT and 677CT than in those with 677CC (61% and 45%, respectively; OR, 1.97; P <0.01) (TABle 4). A higher incidence of adverse effects was also found in the group of patients with genotype GGH 401CC compared with those with genotypes GGH 401CT and GGH 401TT (79% and 52%, respectively; OR, 3.8; P = 0.053) and in patients with at least 1 TYMS 3R allele compared with other patients (56% and 40%, respectively; OR, 1.97; P = 0.056) ( 18 demonstrated that RA patients with the RFC-1 80AA genotype had higher MTXP concentrations, lower numbers of swollen joints, and lower scores on the visual analogue scale than patients with the RFC-1 80G/G and G/A polymorphisms. However, the authors could not confirm the results in a prospective study on 48 patients. 16 Drozdzik et al.
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studied the effect of the RFC-1 c.80G>A polymorphism on the effectiveness of MTX therapy in 174 RA patients treated with MTX. The chance for achieving remission was 3.3-fold higher in patients with genotype 80AA than in those with 80GG. An increase in aminotransferase activity was also more common among patients with genotype 80AA, but because of the low number of patients, these differences were not significant. 19 However, the presence of the RFC-1 80A allele was also associated with a more common
The effect of individual polymorphisms on specific adverse effects was also analyzed. Increased aminotransferase activity was more common in patients with genotypes MTHFR 677CT and 677TT compared with those with genotype MTHFR 677CC (11% and 3%, respectively; OR, 3.4; P = 0.025) and in RFC-1 80AA homozygotes compared with RFC-1 80GA + RFC-1 80GG ones (16% and 5%, respectively; OR, 3.4; P = 0.01). Genotype RFC-1 80AA was also characterized by a higher risk of hair loss compared with RFC-1 80GA + RFC-1 80GG (20% and 10%, respectively; OR, 2.4; P = 0.049) ( Homocysteine and folic acid concentrations were not increased after 6 months of MTX therapy.
DIsCUssION MTX is used in more than 0.5 million patients with RA worldwide. Routinely determined clinical and laboratory parameters are weak prognosticators of the response to MTX therapy. In our study, we also found no effect of sex, the presence of rheumatoid factor, use of corticosteroids, smoking, or disease stage on the efficacy of the MTX therapy.
Based on published studies, it is difficult to state clearly which polymorphisms would be good Abbreviations: see TABle 3 with RA treated with MTX. They demonstrated that individuals with the GGH 16C allele have a 2.9-fold higher chance for DAS reduction by over 1.2 compared with patients with the TT genotype. A lack of the effect of GGH c.16T>C and GGH c.452 C>T polymorphisms on the efficacy of therapy was confirmed in several other studies on patients with RA and inflammatory bowel disease. 22, 23 In the present study, we evaluated only the GGH c.-401C>T polymorphism. We found no effect of this polymorphism on the efficacy of the therapy. However, we observed a higher incidence of adverse effects in the group of patients with the GGH 401CC genotype, which could be associated with higher cellular MTXPG levels.
The analysis of the effect of MTHFR polymorphisms in RA patients treated with MTX also provided contradictory results. van Ede et al. 13 evaluated the role of the c.677C>T polymorphism in 236 patients with RA. MTX therapy had to be discontinued more often because of adverse effects in patients with the T allele, mostly because of increased aminotransferase activity. The study did not demonstrate an effect of the genotype on the efficacy of therapy. 13 Studies performed in Hindu (150 patients) and Chinese populations (193 patients) did not show an effect of the c.677C>T polymorphism on the efficacy of therapy and the incidence of adverse effects. The authors explained this by the low number of patients, low doses of MTX (mean dose, 9.4 mg/wk), lack of folic acid use, and effect of other polymorphisms. 28, 29 One of the very few studies which precisely defined the type and severity of adverse effects was a study by Kim et al. 30 The presence of 677CT or 677TT homozygotes was associated with a 4-fold higher incidence of adverse effects compared with CC homozygotes. 30 Different results were obtained in a study of 63 patients with RA, psoriatic arthritis, polymyositis, and ankylosing spondylitis. 31 The study showed that adverse effects were more common in a group of patients with the 677CC genotype. It should be noted that the study group was heterogeneous in relation to the type of disease, the number of patients was low, and adverse effects were analyzed as a whole. 31 In 3 other studies on occurrence of adverse effects, especially in combination with the TYMS 3-UTR 6-bp del allele. 20 Different results related to the RFC-1 polymorphism and adverse effects were obtained by other investigators. The RFC-1 80GG genotype significantly increased the risk of all adverse effects and was associated with a 15-fold increase in the risk of infection compared with the RFC-1 AA/ AG genotype. 17 However, Fukino et al. 21 did not show any effect of the RFC-1 polymorphism on serum MTX concentrations in 100 patients with RA, 21 and several other studies did not confirm any effect of the polymorphism on the efficacy of therapy and adverse effects during the MTX therapy. 22, 23 In this study, we demonstrated no association between the RFC-1 c.80G>A polymorphism and the efficacy of therapy, but similarly to some other studies mentioned above, an increase in aminotransferase activity and hair loss were observed more often in patients with the RFC-1 80AA genotype. There are also other mechanisms allowing folate transport into the cell, which may explain the lack of the effect of the RFC-1 polymorphisms in some studies.
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The clinical significance of polymorphisms in the FPGS and GGH genes has not yet been established. Several studies evaluated the effect of GGH/FPGS polymorphisms on MTX therapy in RA patients. Among 226 patients with RA treated with MTX, lower MTXPG concentrations were found in patients with the GGH 401TT genotype, and this could be associated with resistance to MTX. However, the authors failed to confirm those results in a prospective study.
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The c.452C>T polymorphism in the GGH gene reduces the catalytic activity of GGH and increases the accumulation of long-chain MTXPG, which may affect the efficacy of MTX therapy. 25 However, van der Straaten et al. 26 did not find any effect of that polymorphism on the efficacy and incidence of adverse effects during MTX therapy. It seems that the ratio of GGH to FPGS activity is more important for the MTXPG concentration than the separate activities of these enzymes.
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van der Straaten et al. 26 studied the effect of polymorphisms of the FPGS and GGH genes on therapy efficacy and adverse effects in 352 patients and TABle 3 and a reduction of adverse effects to a minimum and allow individualization of treatment. However, it should be noted that genetic predisposition is only one of the numerous factors affecting the effects of pharmacotherapies in individual patients.
Conclusions Studies on gene polymorphisms may allow to determine a group of patients with a predisposition to higher efficacy of MTX therapy or to the development of adverse effects during the therapy. Patients with the MTHFR 677TT and 677CT and GGH 401CC genotype have a higher risk of developing adverse effects. Because of the increased risk of hepatotoxicity, aminotransferase activity should be determined more often in patients with the MTHFR 677CT and 677TT genotype and in RFC-1 80AA homozygotes. Studies on the frequency of the 677T allele in the MTHFR, 401C allele in GGH, and 80A allele in RFC-1 genes require continuation and evaluation in a large group of RA patients to determine their roles as factors predisposing to some adverse effects during MTX therapy.
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the effect of the MTHFR polymorphisms, a significant increase in the rate of adverse effects was demonstrated in the group of patients with the 677TT variant. [32] [33] [34] In our study, we observed only a more rapid positive response to MTX therapy and a trend for a better response to therapy in CC homozygotes. A higher incidence of adverse effects was found among patients possessing at least 1 T allele. An increase in aminotransferase activity was observed over 3 times more often in those patients. Several studies also evaluated the effect of a second polymorphism within the MTHFR. In their meta-analysis involving 5 studies, Fisher et al., 32 as in this study, did not show any effect of the c.1298A>C polymorphism on the incidence of adverse effects. Other studies also did not demonstrate any effect on therapy efficacy. 23, 35 Several studies also evaluated the role of the TYMS polymorphism among RA patients. Theoretically, patients with the 3R allele (mainly homozygotes) and with the 6-bp ins allele should experience fewer adverse effects, mostly related to tissues made of fast-dividing cells. However, this was not confirmed in all studies, which indicates the influence of numerous other factors on the development of adverse effects. 16, 36 A role for those polymorphisms may be certified by the necessity for higher doses of MTX to achieve similar therapeutic effects in patients who were 3R/3R homozygotes and by the higher reduction of CRP levels found in patients who were homozygotes in relation to the 6-bp deletion in TYMS. 37 However, the results obtained in that study can hardly be compared with those of the present study, because in the case of both TYMS polymorphisms, the frequency of the allele is different in Asian and European populations, lower MTX doses were used, and there were different criteria of improvement. In their study on 214 patients with RA, Weisman et al.
38 demonstrated a more frequent incidence of hair loss in patients with the TYMS 2R/2R. Different results were published recently by Bohanec et al. 17 The TYMS 3R/3R polymorphism was associated with a more common incidence of hematological adverse effects, but it had no effect on the efficacy of therapy. Similarly to Bohanec et al., 17 we could not demonstrate the effect of the TYMS 2R/3R polymorphism on the efficacy of therapy, but fewer adverse effects were observed in TYMS 2R homozygotes.
The results for MTHFRc. 1298A>C and TC c.593T>C polymorphisms should be interpreted with caution (despite the lack of correlation shown) because of the observed deviation from the HWE.
Furthermore, the use of a genome-wide association strategy is likely to reveal novel predictors of MTX response. 39 There is a chance that future individualization of therapy will allow to adapt the applied treatment to a particular molecular subtype of a disease and the patient's genotype. The further development of pharmacogenetics will contribute to improved efficacy of therapies
